SPIE Photonics West Digital Forum Showcases Best of Optics, Photonics, Quantum, Biomedical Technologies in Applications and Research
17.3.2021 19:08:00 EET | Business Wire | Press release
SPIE, the international society for optics and photonics, welcomed an engaged global audience to its SPIE Photonics West Digital Forum 6-11 March with 8,000 registered attendees. Across the highly regarded BiOS, LASE, and OPTO symposia, as well as the new industry-focused Quantum West conference, SPIE Photonics West showcased more than 20 plenary speakers, including Ursula Keller, Gérard Mourou, Susumu Noda, Satoshi Kako, Kohji Mitani, Sheila Nirenberg, Laura Fabris, and Yeka Aponte. More than 100 live events – including panel sessions, technical discussions, and networking events complemented the 3,200 on-demand presentations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005651/en/
SPIE Photonics West Digital Forum showcases best of optics, photonics, quantum, biomedical technologies in applications and research (Photo: Business Wire)
In addition, two Digital Marketplaces – one for Photonics West, one for BiOS – together showcased more than 400 exhibitors and over 100 product demonstrations of the latest innovations in optics and photonics.
The largest photonics virtual event of 2021, SPIE Photonics West spotlighted and recognized the best optics and photonics technologies, trends, and entrepreneurial innovations, offering many opportunities for attendees, presenters, scientists, and engineers to engage and discuss their latest research and work. From COVID-focused diagnostics advancements and neuro-technologies to lasers in manufacturing and data center communications, SPIE Photonics West offered a dynamic week of information sharing, learning, and conversation.
Quantum West, a new conference on quantum technology held in partnership with the QED-C, featured industry leaders such as Celia Merzbacher, Peter Knight, Andrew Lord, Wilhelm Kaenders, and Kaitlin Moore exploring the role of photonics in quantum technology’s growth from R&D into engineering products for commercial applications.
"I have worked with SPIE over many years, as both an exhibitor and conference chair, and am very happy to help build Quantum West together with them,” said Quantum West Co-Chair Tim Day who serves as DRS Daylight Solutions GM and senior VP, as well as Member of the Board of ColdQuanta. “SPIE did a great job under challenging circumstances and is always a wonderful partner in terms of bringing the community together and helping to advance photonics technology. We, along with many others in the photonics community, are looking forward to an in-person meeting next January in San Francisco.”
Other industry-focused events featured live sessions with thought leaders discussing today’s hottest application areas, including industrial lasers, sensing and imaging, and autonomous vehicles.
“I come to Photonics West every year with my students,” said Jennifer Barton, who is co-chair for BiOS as well as the director of the University of Arizona’s BIO5 Institute and the university’s Thomas R. Brown Distinguished Professor of Biomedical Engineering. “This year, three of them presented virtually, along with myself. I was very impressed with the high quality of live and prerecorded presentations, the flawless execution of events, and the surprisingly effective opportunities for networking and fun – go Trivia Night! Of course, I am looking forward to seeing everyone in person next year, but I loved how engaging and informative this conference week was.”
“Photonics West is the largest biomedical, laser, and optoelectronic event in our field, even when we cannot travel,” noted SPIE Senior Director of Technical Programs Marilyn Gorsuch. “Given the virtual circumstances, our volunteer conference chairs rolled up their sleeves and produced an amazing offering to present and discuss the latest technical advancements. But nothing can replace the in-person experience and the excitement of gathering together at Photonics West in San Francisco. We are very much looking forward to hosting Photonics West in San Francisco next January.”
All the Photonics West content will be available on the SPIE Digital Library from 20 March.
Photonics West 2022 will take place 22-27 January at the Moscone Center in San Francisco. The Call for Papers will be announced and open in the next few weeks.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005651/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release
Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release
Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 14:30:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesi show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 14:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom